October 7th 2025
The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.
Catalent, Ethicann Partner on Fast-Dissolve Cannabinoid Treatment for MS Spasticity
December 5th 2019Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.